Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Abstract Background The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monotherapy in reducing disease activity and signs and s...

Full description

Bibliographic Details
Main Authors: Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, Chieh-I Chen, Matthew Reaney, Sophie Guillonneau, Toshio Kimura, Janet van Adelsberg, Yong Lin, Erin K. Mangan, Hubert van Hoogstraten, Gerd R. Burmester
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Arthritis Research & Therapy
Subjects:
Sarilumab
Adalimumab
Biologic disease-modifying antirheumatic drugs
Rheumatoid arthritis
Patient-reported outcomes
Online Access:http://link.springer.com/article/10.1186/s13075-018-1614-z

Internet

http://link.springer.com/article/10.1186/s13075-018-1614-z

Similar Items